iShares Biotechnology ETF

IBB

Market cap $8.65B

NVIDIA Corp.'s (NASDAQ: NVDA) and Eli Lilly and Co.'s (NYSE: LLY) newly announced $1 billion AI co-innovation lab underscores how artificial intelligence is spreading beyond data centers into medicine, and ETF investors are beginning to price that into thematic funds.

Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

Michael Yee, global head of biotech research at UBS, joins CNBC's ‘Squawk on the Street' to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.

Kentucky-based Aristides Capital sold 28,467 shares of IBB in the third quarter. The shares were worth an estimated $3.60 million.

The AI trade has been wobbling quite a bit in recent weeks, to say the least. And while the popping of the AI bubble hasn't yet happened, it does seem like much of the damage done to particular overheated AI stocks has been a bit overdone.

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.

The approval of Novo Nordisk's (NYSE: NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company.

CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.